Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.
The firms will use the funds to integrate FYR's liquid biopsy platform in NuvOx's Phase II trial evaluating the oxygen therapeutic NanOâ‚‚ as a radiosensitizer.
The Shanghai-based firm will evaluate the safety of the therapy and its efficacy in reducing urinary oxalate levels and improving renal outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback